Skip to content
Review Open access

Cancer Therapeutics-Related Cardiac Toxicity and Heart Failure: Current Evidence and Unresolved Challenges

Oct 2026 · International Journal of Heart Failure · Vol 8, pp. 288 - 307 · 0 citations · 138 references
Medicine

Abstract

As cancer survival continues to improve, cancer therapy-related cardiovascular toxicity, including cancer therapeutics-related cardiac dysfunction (CTRCD) and heart failure (HF), has emerged as a major clinical challenge. Growing evidence supports a bidirectional relationship between cancer and HF, driven by shared risk factors, overlapping pathophysiological mechanisms, and the cardiotoxic effects of anticancer therapies. Advances in imaging modalities and cardiac biomarkers have enabled earlier detection of subclinical myocardial injury. Preventive strategies including modification of cancer therapy and pharmacologic cardioprotection have been extensively investigated. However, randomized trials evaluating neurohormonal antagonists, statins, and other agents have yielded heterogeneous results, and most evidence derives from selected populations. Management of asymptomatic and symptomatic HF in patients with cancer generally follows current HF guidelines, yet major HF trials have largely excluded patients with active or recent malignancy. Consequently, uncertainties remain regarding optimal prevention and treatment strategies in cancer patients. This review focuses on CTRCD and the HF associated with it, and summarizes current evidence on risk assessment, early detection, prevention, and management, while highlighting unresolved challenges and future directions.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.